GHK-Cu: The Peptide Everyone Is Injecting (Big Mistake?)
A urologist reviews the published evidence on GHK-Cu, arguing the topical data is solid while injectable use has no human trials, and covers copper safety and FDA status.
With Dr. Alex Tatem (board-certified urologist, fellowship-trained men's health specialist)
Key moments
Tap a moment to play the video from there.
- 0:00Copper peptide hype versus realityTatem introduces GHK-Cu as a peptide moving from face creams into syringes and lists the claims made for it, including skin, hair and wound effects.
- 1:01Topical data, no injectable trialsHe says the cream and serum forms have data, while the injectable version has zero published human clinical trials.
- 3:00What GHK-Cu isHe explains the name, the copper complex and its small size, and says plasma levels fall from about 200 ng/mL at 20 to about 80 ng/mL at 60.
- 5:05Discovery by Loren PickartTatem recounts how Pickart found the factor in plasma that made older liver cells behave like younger ones, and how the sequence was confirmed in 1977.
- 7:22Copper shuttle mechanismHe describes GHK-Cu as a copper ionophore that binds copper tightly, and compares its binding to that of albumin.
- 8:59The 4,000 genes claimHe says gene expression analyses show over 4,000 genes affected, and reviews collagen, matrix and inflammation pathways, largely from cell and preclinical work.
- 14:09From skincare to injectionsTatem traces the move from wound research to cosmetics, says topical skin data is solid, and explains why people turned to injection.
- 17:35Injectable dosing is forum consensusHe says protocols such as 1 to 2 mg daily for 30 to 60 day cycles come from forums and practitioners, not clinical guidelines.
- 21:01Copper uglies explainedHe describes users reporting worse-looking skin and offers a theory that collagen breakdown outpaces rebuilding in some people.
- 22:48Safety and copper loadTatem covers reassuring cell and preclinical safety data, local injection reactions, copper accumulation, Wilson's disease and angiogenesis questions.
What the video says
Dr. Alex Tatem, a urologist who runs a men's health center, walks through GHK-Cu, the copper-binding tripeptide found in skincare products and now sold for injection. He frames the video around one gap: he says topical use has human data, while subcutaneous use has zero published human clinical trials. The tone is joking and informal, with frequent asides, but the content follows the published literature.
He starts with the basics. GHK-Cu is a three amino acid peptide bound to copper, and he says the body makes it naturally, with plasma levels falling from about 200 ng/mL at age 20 to about 80 ng/mL at age 60. He recounts its discovery in the 1970s by Loren Pickart and explains the proposed mechanism: GHK carries copper into cells while keeping the metal's reactive effects in check. He describes gene expression analyses suggesting it influences over 4,000 genes, plus cell culture and preclinical findings on collagen, matrix remodeling, inflammation, fibrosis and neuroprotection. He stresses that much of this is not human data.
The middle of the video traces how it moved from wound research to cosmetics to injection. Tatem says controlled human studies support topical GHK-Cu for skin quality, and that hair evidence is still thin. He describes online injectable protocols of 1 to 2 mg daily as forum consensus rather than clinical guidance. He lists what users report, including skin texture changes, faster recovery from cuts, mixed hair results, and the so-called copper uglies, which he links to a possible imbalance between collagen breakdown and rebuilding.
He then covers risks. He calls the safety record in the available data favorable, but raises copper load from daily injections, Wilson's disease, copper and zinc balance, angiogenesis, missing pharmacokinetics and sourcing. The last section explains the 2023 FDA category decisions, a February 2026 announcement by Robert F. Kennedy Jr. about moving peptides back to category one, and why Tatem says compounding eligibility is not approval. His verdict is cautious: plausible mechanism, strong topical case, unproven injectable case.
On each compound
GHK-Cu3:00
Tatem describes GHK-Cu as a naturally occurring copper-binding tripeptide and says topical use has human data for skin quality. He says injectable use has no published human trials, no standard dosing and no measured human pharmacokinetics.
See how your DNA reads GHK-Cu“Compounding eligibility is not the same as FDA approval.”
What this video doesn’t settle
- It does not establish whether injectable GHK-Cu produces any of the reported benefits in people, since no human trials of that route are cited.
- The 4,000 gene claim and most mechanism findings come from gene expression analyses, cell culture and preclinical studies, not human outcomes.
- The copper safety reasoning relies on user reports and a calculation from typical forum doses, with no human pharmacokinetic or long-term safety data.
Questions this video answers
Is there human clinical trial evidence for injectable GHK-Cu?
Tatem says there are zero published human clinical trials of subcutaneous GHK-Cu for any indication. He says reported benefits are extrapolated from topical human studies, preclinical studies, cell culture work and user anecdotes.
What does Dr. Alex Tatem say about topical GHK-Cu for skin?
He says controlled human studies on aged skin reported improvements in firmness, elasticity, fine lines and density with topical use. He calls this the solid part of the GHK-Cu story, while noting that skin absorbs little of the peptide without enhancement.
What are the copper uglies with GHK-Cu?
Tatem describes them as an online term for skin looking worse after starting GHK-Cu. He offers a theory that collagen breakdown runs faster than rebuilding in some people, and says users report it clears within two to four weeks of stopping.
What safety concerns does Tatem raise about injecting GHK-Cu?
He mentions injection site redness and itching, possible copper accumulation since injection bypasses gut absorption controls, and the copper and zinc balance. He says people with Wilson's disease or liver dysfunction should stay away, and that others should consider monitoring copper levels.
Is injectable GHK-Cu legal according to this video?
Tatem says the FDA placed topical GHK-Cu in category one for compounding in 2023 but restricted the injectable form. He says Kennedy announced plans to reclassify about 14 peptides, but no formal rule had been published when he recorded.
Video by Dr. Alex Tatem on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
